ACE | Angiotensin I converting enzyme | Candidate cardiovascular disease genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Group enriched |
ACHE | Acetylcholinesterase (Yt blood group) | Blood group antigen proteins Enzymes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |
AMY2A | Amylase, alpha 2A (pancreatic) | Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Tissue enriched |
AOC3 | Amine oxidase, copper containing 3 | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
BLVRB | Biliverdin reductase B (flavin reductase (NADPH)) | Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Expressed in all |
C3 | Complement component 3 | Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
C4A | Complement component 4A (Rodgers blood group) | Blood group antigen proteins Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Expressed in all |
C4B | Complement component 4B (Chido blood group) | Blood group antigen proteins Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Expressed in all |
CA14 | Carbonic anhydrase XIV | Enzymes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CA4 | Carbonic anhydrase IV | Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CACNA2D1 | Calcium channel, voltage-dependent, alpha 2/delta subunit 1 | FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins Transporters
| | | | | Mixed |
CD2 | CD2 molecule | CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD3D | CD3d molecule, delta (CD3-TCR complex) | CD markers Disease related genes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD3G | CD3g molecule, gamma (CD3-TCR complex) | CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD4 | CD4 molecule | CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
CD44 | CD44 molecule (Indian blood group) | Blood group antigen proteins Cancer-related genes CD markers FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
CD80 | CD80 molecule | CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD86 | CD86 molecule | CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Mixed |
CES1 | Carboxylesterase 1 | Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Group enriched |
CHRNA7 | Cholinergic receptor, nicotinic, alpha 7 (neuronal) | FDA approved drug targets Predicted membrane proteins Predicted secreted proteins Transporters
| | | | | Mixed |
CSF3R | Colony stimulating factor 3 receptor (granulocyte) | Cancer-related genes CD markers Disease related genes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
CYP17A1 | Cytochrome P450, family 17, subfamily A, polypeptide 1 | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
DBH | Dopamine beta-hydroxylase (dopamine beta-monooxygenase) | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
DPEP1 | Dipeptidase 1 (renal) | Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Tissue enhanced |
DPP4 | Dipeptidyl-peptidase 4 | CD markers Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
EGFR | Epidermal growth factor receptor | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enhanced |
ELANE | Elastase, neutrophil expressed | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
ERBB2 | V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
F2 | Coagulation factor II (thrombin) | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
F8 | Coagulation factor VIII, procoagulant component | Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Expressed in all |
FCGR2A | Fc fragment of IgG, low affinity IIa, receptor (CD32) | CD markers FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Mixed |
FCGR2B | Fc fragment of IgG, low affinity IIb, receptor (CD32) | Cancer-related genes CD markers Disease related genes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |
FCGR3A | Fc fragment of IgG, low affinity IIIa, receptor (CD16a) | CD markers FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
FGA | Fibrinogen alpha chain | Cancer-related genes Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
FGFR2 | Fibroblast growth factor receptor 2 | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Mixed |
FLT1 | Fms-related tyrosine kinase 1 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enriched |
FN1 | Fibronectin 1 | Cancer-related genes Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Expressed in all |
GABRA1 | Gamma-aminobutyric acid (GABA) A receptor, alpha 1 | Disease related genes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |
GANAB | Glucosidase, alpha; neutral AB | Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Expressed in all |
ICAM1 | Intercellular adhesion molecule 1 | Cancer-related genes Candidate cardiovascular disease genes CD markers FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
IDE | Insulin-degrading enzyme | Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Expressed in all |
IL2RB | Interleukin 2 receptor, beta | Cancer-related genes CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
ITGAL | Integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide) | CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
ITGB1 | Integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) | Cancer-related genes CD markers FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
LHCGR | Luteinizing hormone/choriogonadotropin receptor | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
LIPF | Lipase, gastric | Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Tissue enriched |
MET | Met proto-oncogene | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Mixed |
MMP10 | Matrix metallopeptidase 10 (stromelysin 2) | Cancer-related genes Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Tissue enriched |
MMP11 | Matrix metallopeptidase 11 (stromelysin 3) | Cancer-related genes Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Group enriched |
MMP8 | Matrix metallopeptidase 8 (neutrophil collagenase) | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |